Copy Link Print Information

Ladiratuzumab

(Synonyms: hLIV22)
Customer Review

Based on 1 Customer Validation

Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC).

For research use only. We do not sell to patients.

  • Purity : 99.76%
  • CAS No.: 1629760-28-6
  • Molecular Weight:146.96 kDa
  • Storage:
    Shipping with dry ice

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Ladiratuzumab
  • Experimental Validation Results for Ladiratuzumab
  • Experimental Validation Results for Ladiratuzumab
  • Ladiratuzumab Chemical Structure
    Ladiratuzumab Chemical Structure
CAS No.: 1629760-28-6
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Ladiratuzumab Product Recommendations:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Keywords

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 kappa

  • 1/16

    Immobilized LIV-1/SLC39A6 Protein, Human (HEK293, HY-P78749) can bind Ladiratuzumab. The ED50 for this effect is 2.230 ng/mL.

  • 1/16

    Flow cytometric analysis of 1X106 MCF-7 cells labeling SLC39A6 with Ladiratuzumab (HY-P99682, red). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • Ladiratuzumab Chemical Structure
    1/16
  • Ladiratuzumab
  • Immobilized LIV-1/SLC39A6 Protein, Human (HEK293, HY-P78749) can bind Ladiratuzumab. The ED50 for this effect is 2.230 ng/mL.
  • Flow cytometric analysis of 1X106 MCF-7 cells labeling SLC39A6 with Ladiratuzumab (HY-P99682, red). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).